Clinical Trial Update: Evaluation of Miricorilant on Liver Fat in Patients With MASLD [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Miricorilant on liver fat in patients with MASLD, including NASH and related conditions; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Metabolic Dysfunction-associated Steatotic Liver Disease
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Miricorilant (CORT118335)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 | Status: RECRUITING